EUVIMEDEUVIMED entdecken
Open Access

Deletion of thymic myoid cells regulates the thymic microenvironment involved in the progression of tumor-associated myasthenia gravis

Bo Hu, Yang Luo, Xiangyu Ding, Min Sun, Li Niu iD

Clinical and Experimental Immunology · 2025

DOI: 10.1093/cei/uxaf043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Bo Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Thymus Gland, Tumor Microenvironment, Thymus Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Research Project of Anhui Educational Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) is an autoimmune disease commonly associated with immune disorders in thymoma. The role of thymus myoid cells (TMCs) in the pathogenesis of autoimmune diseases has attracted much attention. Therefore, the present study was designed to reveal the impact of TMCs on the pathophysiology of tumor-associated MG (TAMG). This study included clinical patients and healthy volunteers and validated the potential role of TMCs in TAMG progression using a TMCs-deficient mouse model. Correlative findings showed that TMCs deletion affected thymic architecture in MG patients, as evidenced by the expression of key myogenic factors as well as AChR and RyRs receptors in the thymus. Further experimental validation showed that TMCs deletion increased the levels of Th1 and Th17 cells, decreased the levels of Th2 and Treg cells, and altered the secretion of corresponding cytokines, including IL-2, IL-4, IL-17, IL-22, and TGF-β concentrations. Co-culture of CD4+ T cells with Thy0517 cells or CD4+ T cells with a myoblastoid cell line using the Transwell system demonstrated that deletion of TMC inhibited the differentiation of CD4+ T cells to Treg cells. In this study, we hypothesized that TMCs are involved in TAMG progression by regulating CD4+ T cell differentiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisThymus GlandTumor MicroenvironmentThymus NeoplasmsHumansAnimalsMiceFemaleMaleT-Lymphocytes, RegulatoryDisease ProgressionMiddle AgedCell DifferentiationCytokinesAdultThymomaTh17 CellsDisease Models, Animal

Stichwörter der Autor:innen

CD4+ T cellsTreg cellsthymoma-associated myasthenia gravisthymus myoid cells

Substanzen

Cytokines

Autor:innen und Institutionen

  • Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • Department of Radiotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

ORCID-Profile: Li Niu

Förderung

  • Natural Science Research Project of Anhui Educational Committee

Zitieren

APA

Hu, B., Luo, Y., Ding, X., Sun, M., & Niu, L. (2025). Deletion of thymic myoid cells regulates the thymic microenvironment involved in the progression of tumor-associated myasthenia gravis. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf043

Vancouver

Hu B, Luo Y, Ding X, Sun M, Niu L. Deletion of thymic myoid cells regulates the thymic microenvironment involved in the progression of tumor-associated myasthenia gravis. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxaf043

BibTeX
@article{Hu2025,
  author = {Hu, Bo and Luo, Yang and Ding, Xiangyu and Sun, Min and Niu, Li},
  title = {Deletion of thymic myoid cells regulates the thymic microenvironment involved in the progression of tumor-associated myasthenia gravis},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  doi = {10.1093/cei/uxaf043}
}
Kostenlos starten →